Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma.

MLA

Nawar, Nabanita, et al. “Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma.” Journal of Medicinal Chemistry, vol. 65, no. 4, Feb. 2022, pp. 3193–217. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.1c01585.

APA

Nawar, N., Bukhari, S., Adile, A. A., Yujin Suk, Manaswiyoungkul, P., Toutah, K., Olaoye, O. O., Raouf, Y. S., Sedighi, A., Garcha, H. K., Hassan, M. M., Gwynne, W., Israelian, J., Radu, T. B., Geletu, M., Abdeldayem, A., Gawel, J. M., Cabral, A. D., Venugopal, C., & de Araujo, E. D. (2022). Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma. Journal of Medicinal Chemistry, 65(4), 3193–3217. https://doi.org/10.1021/acs.jmedchem.1c01585

Chicago

Nawar, Nabanita, Shazreh Bukhari, Ashley A. Adile, Yujin Suk, Pimyupa Manaswiyoungkul, Krimo Toutah, Olasunkanmi O. Olaoye, et al. 2022. “Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma.” Journal of Medicinal Chemistry 65 (4): 3193–3217. doi:10.1021/acs.jmedchem.1c01585.